Discussing which biotechs may have been oversold in the selloff, with Michael Yee, RBC Capital biotech analyst.» Read More
Alexandria Real Estate Equities founder, chairman and CEO Joel Marcus discuss its firm's success, and how rising yields impact its dividend.
Alexandria Real Estate Equities founder, chairman and CEO Joel Marcus discuss real estate demand in the biotech industry.
Perrigo CEO Joseph Papa provides insight on the current flu season, and how it plans on getting its name better known.
Perrigo CEO Joseph Papa discusses how its new headquarters in Ireland will impact its tax structure, and whether the company will add a dividend.
Biogen Idec CEO George Scangos discusses the busy year ahead for the company, including the EU launch of Tecfidera and when a dividend will be offered.
The Supreme Court upheld Monsanto's biotech seed patents on Monday, dealing a blow to organic farmers and critics of the company.
The outlook for biotech is "wonderful," explains Sam Isaly, Orbimed Advisors managing partner.
Shares of Intercept Pharmaceuticals are up more than 560 percent this week alone. Akiva Felt, Oppenheimer senior analyst, shares his optimistic view for the company.
Daryl Liew, Head Of Portfolio Management of REYL Singapore advises investors to look past short-term volatilities in the country's economy after Q4 GDP data missed expectations
CNBC's Seema Mody reports the biotech index has hit an all-time high in the Nasdaq.
Johnson & Johnson and its subsidiaries were accused of promoting powerful psychiatric drugs for unapproved uses in children, seniors and disabled patients.
CNBC's Seema Mody reports on the biggest movers in the Nasdaq including social media stocks like Facebook up 5 percent.
Francois Nader, NPS Pharmaceuticals president & CEO, discusses its lead product Gattex for "short bowel syndrome," the potential for Netpara and the solid performance of its stock.
Biotech stocks are some of Nasdaq's best performing this year. Joel Sendek, Stifel Nicolaus, looks at names leading the biotech boom.
How are biotech companies and the FDA impacted by the government shutdown? Yaron Werber of Citi Investment Research, offers insight.
Mad Money host Jim Cramer calls Array BioPharma a spec play. The company has 6 trials in phase 3 in progress. Its CEO Ron Squarer discusses its partnerships with big players including Novartis and Celgene.
Zac Vawter has been fitted with the first thought-controlled bionic leg, scientists at the Rehabilitation Institute of Chicago reported.
Want to avoid taking a hit on your portfolio because of troubles in Washington? Cramer found one sector that will be a shelter from the storm.
Amgen has struck a $10 billion-plus deal to buy Onyx Pharmaceuticals, ending a two-month-long auction for the cancer drugmaker.
Amgen is close to buying Onyx for $125 per share, or more than $10 billion, in a deal that is expected to be announced as soon as Monday, two people familiar with the matter said on Saturday.